Magnetic resonance imaging of myocardial infarction using a manganese‐based contrast agent (EVP 1001‐1): Preliminary results in a Dog model

To investigate the MRI characteristics of an intracellular manganese‐based contrast agent, EVP 1001‐1 (Eagle Vision Pharmaceutical Corp.), in a canine model of myocardial infarction.

[1]  Kang Ys,et al.  Studies of tissue NMR relaxation enhancement by manganese. Dose and time dependences. , 1984 .

[2]  F. Buonanno,et al.  Proton nuclear magnetic resonance imaging of regionally ischemic canine hearts: effect of paramagnetic proton signal enhancement. , 1982, Radiology.

[3]  Han Wen,et al.  Does binding of Gd‐DTPA to myocardial tissue contribute to late enhancement in a model of acute myocardial infarction? , 2003, Magnetic resonance in medicine.

[4]  S. Seltzer,et al.  Safety and Efficacy of Mangafodipir Trisodium (MnDPDP) Injection for Hepatic MRI in Adults: Results of the U.S. Multicenter Phase III Clinical Trials (Safety) , 2000, Journal of magnetic resonance imaging : JMRI.

[5]  G. C. Cotzias,et al.  Manganese metabolism in man: rapid exchange of MN56 with tissue as demonstrated by blood clearance and liver uptake. , 1958, The Journal of clinical investigation.

[6]  Y. Ni,et al.  Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnCl2 , 1997, Acta radiologica.

[7]  L S MAYNARD,et al.  The partition of manganese among organs and intracellular organelles of the rat. , 1955, Journal of Biological Chemistry.

[8]  Sebastian Flacke,et al.  Characterization of viable and nonviable myocardium at MR imaging: comparison of gadolinium-based extracellular and blood pool contrast materials versus manganese-based contrast materials in a rat myocardial infarction model. , 2003, Radiology.

[9]  Peter Kohl,et al.  Spatially and temporally distinct expression of fibroblast connexins after sheep ventricular infarction. , 2004, Cardiovascular research.

[10]  F. Ramires,et al.  Molecular and cellular events at the site of myocardial infarction: from the perspective of rebuilding myocardial tissue. , 2004, Biochemical and biophysical research communications.

[11]  J. Oshinski,et al.  Imaging Time After Gd-DTPA Injection Is Critical in Using Delayed Enhancement to Determine Infarct Size Accurately With Magnetic Resonance Imaging , 2001, Circulation.

[12]  T. Yanaga,et al.  Effect of manganese on transmembrane potential and contractility of atrial muscle. , 1969, The American journal of physiology.

[13]  H. Atkins,et al.  Myocardial positron tomography with manganese-52m. , 1979, Radiology.

[14]  G. Elizondo,et al.  Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. , 1991, Radiology.

[15]  Fang Yang,et al.  Myocardial Infarction and Cardiac Remodelling in Mice , 2002, Experimental physiology.

[16]  C. Higgins,et al.  Normal and infarcted myocardium: differentiation with cellular uptake of manganese at MR imaging in a rat model. , 2000, Radiology.

[17]  G L Wolf,et al.  Cardiovascular toxicity and tissue proton T1 response to manganese injection in the dog and rabbit. , 1983, AJR. American journal of roentgenology.

[18]  Wei Li,et al.  Preliminary Evaluation of EVP 1001-1: A New Cardiac-Specific Magnetic Resonance Contrast Agent with Kinetics Suitable for Steady-State Imaging of the Ischemic Heart , 2003, Investigative radiology.

[19]  J C Gore,et al.  Studies of tissue NMR relaxation enhancement by manganese. Dose and time dependences. , 1984, Investigative radiology.

[20]  W. Bao,et al.  Simultaneous assessment of left‐ventricular infarction size, function and tissue viability in a murine model of myocardial infarction by cardiac manganese‐enhanced magnetic resonance imaging (MEMRI) , 2004, NMR in biomedicine.